Skip to main content
Premium Trial:

Request an Annual Quote

Saladax Secures $9M Loan Facility from GE Capital

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax Biomedical today announced the completion of a $9 million debt financing with GE Capital.

The secured loan facility will be used to support commercialization of Saladax's My5-FU assay, which measures levels of 5-flourouracil, a chemotherapy used in conjunction with other therapies for colorectal cancer and other solid tumors. The test is currently available in the European Union and Australia.

The loan will also be used to develop additional assays, Saladax said.

Based in Bethlehem, Pa., Saladax develops companion diagnostics.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.